Ovarian cancer may start in the fallopian tubes, not the ovaries. Explore the latest research and prevention strategies with Jayanthi Lea, M.D., Division Chief of Gynecologic Oncology at UT Southwestern.
PARP-1 inhibitor drugs can reduce the risk of BRCA- and HRDS-associated ovarian cancer by 70%. New research at UT Southwestern Medical Center may help expand treatment to more patients.